Improvements in clinical cellular immunotherapies
Cellular therapies have evolved within the context of hematopoietic cell transplantation (HSCT). In parallel, adoptive immunotherapies outside of HSCT have also proven the capability of cell based immunotherapies to kill tumors. This particularly gained momentum with advances in genetic engineering. Chimeric antigen receptor modified T lymphocytes (CAR T) targeting CD19 were the first living, genetically modified drugs that received approval in 2017. However, besides effectiveness, tolerability will be the key to clinical success. Our group investigates how to manage pleiotropic systemic inflammatory effects of immunotherapies and thus to improve cancer care.
Lab members
Selected publications
Krüger T, Wehner R, Herbig M, Krater M, Kramer M, Middeke JM, …, Bornhäuser M, von Bonin, M. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease. Front Immunol. 2022;13:1005554
Röhnert MA, Kramer M, Schadt J, Ensel P, Thiede C, Krause SW, …, Oelschlagel, U., von Bonin, M. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia. 2022;36(9):2208-17
Krüger T, Middeke JM, Stölzel F, Mütherig A, List C, Brandt K, Heidrich K, Teipel R, Ordemann R, Schuler U, Oelschlägel U, Wermke M, Kräter M, Herbig M, Wehner R, Schmitz M, Bornhäuser M, von Bonin M. Reliable isolation of human mesenchymal stromal cells from bone marrow biopsy specimens in patients after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020 Jan;22(1):21-26
We established a profound method to measure bone marrow MSCs in patients for the first time. This method has been used to understand and quantify niche changes.
von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, Schmitz M, Platzbecker U, Schetelig J, Bornhäuser M, von Bonin M. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells. 2016 Feb;34(2):357-66.
This study investigates one of the biggest patient cohorts at that time point with steroid refractory GvHD receiving MSCs.
Galleu A, Riffo-Vasquez Y, Trento C, Lomas C, Dolcetti L, Cheung TS, von Bonin M, … Bennett, C.,Dazzi, F. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. 2017;9(416)
Establishment of novel biomarkers to predict MSC response within the context of GvHD.
von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, Wagemaker G, Waskow C. In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS One. 2013 Apr 9;8(4):e60680.
Contact
© Thomas Albrecht
Bonin Lab